NeuralCure AI Announces Partnership with Life Imaging FLA
This partnership immediately positions NeuralCure AI for rapid, real-world application, further solidifying its role as a pioneer in AI-powered healthcare solutions. Unlike traditional AI models that provide generalized insights, NeuralCure AI creates patient-specific digital twins and runs constant treatment simulations, helping physicians make more informed, data-driven decisions without replacing clinical judgment.
TOSS Seal and Cut Bands Combine Precision and Efficiency for Medical Applications

Three key offerings—Beaded Bands, T-Profile Bands, and Custom Seal-Cut (CSC) Bands—stand out for their ability to deliver consistent, reliable seals while cutting polymeric films in a single process. Each band incorporates unique design features and cutting-edge technology tailored to various applications.
Penumbra Launches ACCESS25TM Delivery Microcatheter Designed for Aneurysm Access and Delivery of Elevated Clinical Benefits
“The new ACCESS25 delivery microcatheter has not only proven its tracking capabilities in numerous procedures,” says Dr. Scott McPherson, an interventional neuroradiologist at St. Dominic’s Hospital, “but it has also showcased stability amidst procedural complexities in aneurysm management.”
Kabooxa: New Cutting-Edge Software Assistant Bridges Gap Between AI and Monetization
All around the world, the proliferation of AI tools has decision-makers and business leaders asking each other “What are our needs and how can we use AI to meet them?” The engineers at Kabooxa have solved this contemporary business conundrum by asking another question: “What about an enterprise AI engine that you can leverage to boost performance and ROI?”
Jupiter Endovascular Appoints Fred Ong as CFO
Fred Ong brings more than 30 years of experience in building and growing venture capital-backed healthcare technology companies to his role at Jupiter Endovascular, including playing key roles in fundraising, corporate strategy, operational growth, revenue scale, and M&A exits.
Top 10 Must-Have EMS Vehicle Equipment for Emergency Responders

Modern EMS vehicles require comprehensive medical equipment and supplies, with costs averaging around $19,000 per vehicle to ensure readiness for any emergency scenario.
How to Ensure Your Business Meets FDA Compliance Standards

Business Meets FDA Compliance Standards:
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025
Vidofludimus Calcium’s Activation of Nurr1 reduces neuronal loss and injury directly and Indirectly by decreasing microglial activations in preclinical models.
Tom Arnold Appointed CEO of ViCentra
Tom Arnold brings almost 25 years of extensive leadership experience in diabetes and medical technology and has a strong track record in spearheading commercialization initiatives, business strategy, and product launches for leading medical device companies. He has held key leadership roles at Medtronic, PROCEPT BioRobotics, Boston Scientific, and Sorin Group.
Dr. Samuel A. Joseph Jr. Named Clinical Assistant Professor of Orthopaedic Surgery at HCA/USF Orthopaedic Program

Dr. Samuel A. Joseph Jr. a leader in minimally invasive and complex spine surgery, will bring his wealth of experience and innovative approach to the academic setting, enhancing the educational experience of residents and medical professionals in the field of orthopedic surgery.
Fosun Pharma Received NMPA Approval for Wan Ti Le | (Tenapanor Hydrochloride Tablets)
As the world’s first and currently only approved phosphate absorption inhibitor, Tenapanor Hydrochloride Tablets has been officially approved in China, ushering in a new era of multi-mechanism synergistic phosphate control and offering new hope for patients with hyperphosphatemia on hemodialysis in China.
EPO Grants Key CRISPR Patent to ERS Genomics CVC Portfolio
John E Milad, CEO of ERS Genomics, said: “The EPO’s decision to grant EP 4 289 948 with broad claims reinforces CVC’s leadership position in CRISPR IP in Europe and validates our strategic decision to self-revoke two legacy CRISPR/Cas9 patents. This decision provides our 150+ licensees with greater confidence in their rights, while maintaining CVC’s established patent leadership in Europe.”